Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05247489 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT05247489 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 55 participants.
The verdict
NCT05247489, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Interventions
- DRUG Ruxolitinib 1.5% cream
- DEVICE NB-UVB phototherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2023-12-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05247489
The ClinicalTrials.gov registry entry for NCT05247489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib 1.5% cream is the first listed.
NCT05247489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05247489 about?
NCT05247489 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo". The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
What is the current status of trial NCT05247489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2022-05-05. Estimated completion is 2023-12-19.
What interventions are being tested in trial NCT05247489?
The interventions under investigation include: Ruxolitinib 1.5% cream (DRUG), NB-UVB phototherapy (DEVICE).
Who is sponsoring clinical trial NCT05247489?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.